Indivior (NASDAQ:INDV) Sees Strong Trading Volume

Indivior PLC (NASDAQ:INDV) shares saw an uptick in trading volume on Wednesday . 166,116 shares were traded during mid-day trading, a decline of 44% from the previous session’s volume of 296,104 shares.The stock last traded at $11.90 and had previously closed at $12.17.

Analyst Ratings Changes

Several equities analysts have issued reports on INDV shares. Craig Hallum dropped their target price on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th. Piper Sandler assumed coverage on Indivior in a research note on Tuesday, July 23rd. They issued an “overweight” rating and a $22.00 price target on the stock.

Indivior Price Performance

The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.68 and a current ratio of 0.85. The stock’s fifty day moving average price is $12.68 and its 200-day moving average price is $16.78. The firm has a market cap of $1.53 billion, a PE ratio of 1,109.00 and a beta of 0.69.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The company had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. As a group, equities analysts forecast that Indivior PLC will post 1.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Indivior in the second quarter valued at $188,000. VELA Investment Management LLC acquired a new stake in Indivior in the 2nd quarter valued at about $235,000. XTX Topco Ltd purchased a new position in Indivior during the 2nd quarter valued at about $249,000. Chilton Investment Co. Inc. acquired a new position in Indivior during the fourth quarter worth about $263,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Indivior in the fourth quarter valued at about $368,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.